Nichols & Pratt Advisers LLP MA maintained its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,700 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Nichols & Pratt Advisers LLP MA’s holdings in Bristol-Myers Squibb were worth $652,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of BMY. Ameriprise Financial Inc. increased its holdings in Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after purchasing an additional 2,451,390 shares during the last quarter. Swiss National Bank grew its stake in shares of Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares in the last quarter. State Street Corp grew its stake in shares of Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Bristol-Myers Squibb by 5.4% in the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after acquiring an additional 1,184,652 shares in the last quarter. Finally, Harbour Capital Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 5,377.1% in the second quarter. Harbour Capital Advisors LLC now owns 1,189,789 shares of the biopharmaceutical company’s stock worth $21,353,000 after acquiring an additional 1,168,066 shares in the last quarter. Hedge funds and other institutional investors own 69.51% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.25 on Wednesday. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The firm has a market cap of $99,822.34, a price-to-earnings ratio of 20.60, a P/E/G ratio of 2.40 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the firm earned $0.77 earnings per share. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were given a $0.39 dividend. The ex-dividend date was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.
Several equities analysts have commented on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target for the company. in a research note on Tuesday, August 22nd. Citigroup Inc. set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. Finally, Cowen and Company set a $65.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.93.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Nichols & Pratt Advisers LLP MA Holds Position in Bristol-Myers Squibb Company (BMY)” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2017/11/15/nichols-pratt-advisers-llp-ma-holds-position-in-bristol-myers-squibb-company-bmy-2.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.